Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Clinical trial NCT06857305 · UNKNOWN
Trial details
- NCT number
- NCT06857305
- Sponsor
- Ma Fei，MD
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-13
- Primary completion
- 2026-07-13
- Enrollment
- 192
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.